title: Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report.
abstract: The ability of Plasmodium vivax to relapse is a challenge to its management. Primaquine is the only drug licensed for the eradication of hypnozoites. We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine.
authors: From the Department of Internal Medicine, Roskilde Hospital , Roskilde , Denmark.
authors: Kristina Langholz
authors: KL
authors: Kristensen
authors: Ulrik Bak
authors: UB
authors: Dragsted
mesh_terms: D000962:Antimalarials / Q000008:administration & dosage* / Q000494:pharmacology; D004351:Drug Resistance; D006801:Humans; D016780:Malaria, Vivax / Q000188:drug therapy* / Q000469:parasitology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010966:Plasmodium vivax / Q000187:drug effects* / Q000302:isolation & purification; D011319:Primaquine / Q000008:administration & dosage* / Q000494:pharmacology; D012008:Recurrence
chemical_list: D000962:Antimalarials; D011319:Primaquine